文献速递胸部肿瘤放疗放疗物理与技术

重叠时间是同期EGFR-TKI与胸部放疗患者放射性肺炎的独立危险因素

Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy.
PubMed 文献 · Radiat Oncol · 2021-02-23

该回顾性研究纳入67例同期接受第一代EGFR-TKI与胸部放疗的EGFR阳性NSCLC患者,44.78%(30/67)发生≥2级放射性肺炎,中位发生时间3.48个月。多因素分析显示埃克替尼、同侧肺V30>34%及EGFR-TKI与放疗重叠时间>20天为≥2级放射性肺炎的独立预测因素。

要点

  • 同期第一代EGFR-TKI与胸部放疗的NSCLC患者≥2级放射性肺炎发生率为44.78%。
  • 埃克替尼、同侧肺V30>34%、重叠时间>20天是≥2级放射性肺炎独立预测因素。
  • 建议将EGFR-TKI与放疗重叠时间控制在≤20天以降低放射性肺炎风险。

核心结论

  • 同期第一代EGFR-TKI与胸部放疗的NSCLC患者≥2级放射性肺炎发生率高。
  • 埃克替尼、同侧肺V30>34%及重叠时间>20天是≥2级放射性肺炎的独立预测因素。

研究设计与样本

  • 回顾性研究,纳入2012年1月至2019年12月山东省肿瘤医院收治的67例同期接受第一代EGFR-TKI与胸部放疗的NSCLC患者。

主要发现

  • 44.78%(30/67)患者发生≥2级放射性肺炎,中位发生时间3.48个月(范围1.07-13.6个月)。
  • 多因素分析确定埃克替尼、同侧肺V30>34%、EGFR-TKI与胸部放疗重叠时间>20天为≥2级放射性肺炎独立预测因素。

关键数值与推荐

  • 放射性肺炎经CT诊断并按CTCAE v5.0分级。
  • 同侧肺V30>34%与重叠时间>20天为≥2级放射性肺炎的独立预测因素。

临床怎么用

  • 对同期接受第一代EGFR-TKI与胸部放疗的NSCLC患者,可考虑将重叠时间控制在≤20天、同侧肺V30≤34%以降低放射性肺炎风险。
  • 加用胸部放疗应谨慎,并优化治疗策略以减少放射性肺炎发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The exact rate and relevant risk factors of radiation pneumonitis (RP) for non-small-cell cancer (NSCLC) patients treated with the combination of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and thoracic radiotherapy have not been reported. Thus, this study aimed to investigate the rate and risk factors of RP for EGFR-positive NSCLC patients simultaneously treated with first-generation EGFR-TKI and TRT. PATIENTS AND METHODS: We retrospectively evaluated NSCLC patients simultaneously treated with first-generation EGFR-TKI and thoracic radiotherapy between January 2012 and December 2019 at Shandong Cancer Hospital and Institute, Shandong, China. RP was diagnosed via computed tomography and was classified according to the Common Terminology Criteria for Adverse Events v5.0. The risk factors of RP were identified using uni- and multivariate analyses. RESULTS: Of the 67 patients included, 44.78% (30/67) developed grade ≥ 2 RP. Grade ≥ 2 RP occurred within a median of 3.48 (range 1.07-13.6) months. The EGFR-TKI icotinib, ipsilateral lung V30 > 34%, and overlap time of > 20 days between EGFR-TKI and thoracic radiotherapy were identified to be independent predictive factors of grade ≥ 2 RP. CONCLUSIONS: Grade ≥ 2 RP is highly frequent in NSCLC patients simultaneous treated with first-generation EGFR-TKI and thoracic radiotherapy. Icotinib, ipsilateral lung V30 ≤ 34%, and overlap time of ≤ 20 days for EGFR-TKI and thoracic radiotherapy will be helpful to lower the risk of RP in these patients. The addition of thoracic radiotherapy should be cautious, and the treatment strategies can be optimized to reduce the rate of RP for patients treat with simultaneous EGFR-TKI and thoracic radiotherapy.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jia W, Gao Q, Wang M, et al. Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. Radiat Oncol. 2021. PMID: 33622352. doi:10.1186/s13014-021-01765-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。